A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
Abstract
Phase 3 placebo-controlled trial of obeticholic acid in patients with PBC who had inadequate response to or unacceptable side effects with UDCA.
Overview
CoChat Summary
TL;DR
In the 12-month POISE phase 3 trial, obeticholic acid added to ursodiol or given as monotherapy improved the composite biochemical primary end point in patients with primary biliary cholangitis compared with placebo. Obeticholic acid also increased pruritus and serious adverse events.
Key findings
- The primary composite end point occurred in 46% of the 5–10-mg group and 47% of the 10-mg group versus 10% of the placebo group (P<0.001 for both comparisons).
- Alkaline phosphatase decreased by least-squares mean −113 U/L in the 5–10-mg group and −130 U/L in the 10-mg group versus −14 U/L with placebo (P<0.001 for both); total bilirubin changed by −0.02 and −0.05 mg/dL versus +0.12 mg/dL, respectively (P<0.001 for both).
- Noninvasive measures of liver fibrosis did not differ significantly between either obeticholic acid group and placebo at 12 months.
- Pruritus occurred in 56% of the 5–10-mg group and 68% of the 10-mg group versus 38% with placebo; serious adverse events occurred in 16%, 11%, and 4%, respectively.
Methods
- Randomized, double-blind, placebo-controlled, parallel-group, 12-month phase 3 trial at 59 sites in 13 countries; 217 patients underwent randomization and 216 received at least one dose, assigned 1:1:1 to placebo, obeticholic acid 5 mg with adjustment to 10 mg if applicable, or obeticholic acid 10 mg.
- Patients had primary biliary cholangitis with inadequate response to ursodiol or unacceptable ursodiol side effects; 93% received ursodiol as background therapy.
- Primary end point: alkaline phosphatase <1.67× upper limit of normal with ≥15% reduction from baseline and normal total bilirubin at 12 months; analyzed in the intention-to-treat population with Cochran–Mantel–Haenszel testing stratified by randomization factors, with missing values counted as nonresponse.
Limitations
- The paper states that results cover only 2 years of treatment, that the trial focused on surrogate biomarkers, imaging, and symptom end points with no statistical power to assess clinical outcomes, and that multiplicity adjustments were made only for the primary end point and not for secondary or exploratory analyses.
- Evident from the text: the open-label extension was not placebo-controlled, so longer-term durability and crossover findings are uncontrolled.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 12 Not checked · 78 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
What the sources say
- Not checked — no full text of the sourcecites [13] source
- Disputedcites [14] sourceExperimental — accuracy not yet measured
The Discussion’s Systematic review says FXR agonists have indirect anti-fibrotic effects in animal models, contrary to the claim of direct anti-fibrotic effects. The cited passages do not describe direct anti-inflammatory effects or identify such pathways; page numbers are unavailable in our copy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [15] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two 12-week phase 2 studies, daily doses of up to 50 mg of obeticholic acid resulted in reductions from baseline in levels of alkaline phosphatase and bilirubin that were significantly greater than those with placebo. 16”
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Abstract and Primary Efficacy End Point section report one three-month placebo-controlled trial in which daily obeticholic acid doses of 10–50 mg significantly reduced alkaline phosphatase versus placebo. The Secondary End Points section reports lower median conjugated bilirubin with obeticholic acid, but does not state that this reduction was statistically significant versus placebo. This paper therefore does not support the claim about two studies or the stated significance for bilirubin. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, dose-related increases in the incidence and severity of pruritus were evident, particularly at doses of more than 10 mg.”
What the sources say
- Supportedcites [16] source
The Adverse Events section says both pruritus incidence and severity were worse in the 25-mg and 50-mg groups than at 10 mg. It reports severe pruritus in 16%, 24%, and 37% of patients at 10, 25, and 50 mg, respectively. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a large, international cohort analysis involving patients with primary biliary cholangitis, elevations in the alkaline phosphatase level were independently associated with a risk of liver transplantation or death that was 2.0 to 2.5 times as high as the risk associated with normal levels. 10”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (p. 3) says the analyses adjusted for age, sex, year of diagnosis, and UDCA therapy. The Results (p. 4) find higher alkaline phosphatase associated with greater risk of transplantation or death, but compare patients above 2.0 times the upper limit of normal with those at or below that threshold—not specifically with patients whose alkaline phosphatase was normal. The cited passages do not establish the claimed 2.0-to-2.5-fold risk relative to normal levels. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the subgroup of patients who had transient elastography assessed (43%), obeticholic acid was not associated with significant reductions in this noninvasive measure of liver fibrosis at 12 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an intention-to-treat analysis, biochemical response was met in 10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-titrated OCA groups, respectively (p \0.0001 for both).”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue is not related to severity of liver disease, with the exception of very end-stage patients where it is the norm [221], and it is not responsive to UDCA or OCA therapy [6,131].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, OCA was not effective in decreasing PBC-induced liver fibrosis21,22.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
44 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 3×
“(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
BackgroundPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citation
Research works printed but not linked: 1
- Bolier AR, 2012, Acta Gastroenterol Belg, 75, 399
Cited by
Items 301–400 of 1,138
Nuclear receptors in renal health and disease
Luan, Z., Zhang, C., Ming, W., Huang, Y., Guan, Y., & Zhang, X. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103855 · Cited by 39
Autoantibodies in Autoimmune Hepatitis: Can Epitopes Tell Us about the Etiology of the Disease?
Christen, U., & Hintermann, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00163 · Cited by 45
“Recently, obeticholic acid in combination with UDCA has been approved as the first new drug in almost 20 years for treatment of PBC, especially of patient refractory to UDCA single treatment (28, 29).”
BackgroundBeneficial effects of bile acid receptor agonists in pulmonary disease models
Comeglio, P., Morelli, A., Adorini, L., Maggi, M., & Vignozzi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1385760 · Cited by 43
“improved biomarkers in primary biliary cholangitis [70,72], type 2 diabetes, nonalcoholic fatty liver disease [69] and”
BackgroundHussain, A. B., Samuel, R. J., Hegade, V. S., Jones, D. E., & Reynolds, N. J. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17933 · Cited by 37
Self-citationDual Role of Bile Acids on the Biliary Epithelium: Friend or Foe?
Baiocchi, L., Zhou, T., Liangpunsakul, S., Lenci, I., Santopaolo, F., Meng, F., Kennedy, L. L., Glaser, S. S., Francis, H., & Alpini, G. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081869 · Cited by 38
“Obeticholic acid therapy (5–10 mg day) is indeed beneficial, reducing cholestasis indices in PBC patients, including when they are in a concomitant treatment with UDCA [85,86].”
BackgroundManagement of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
Bernal, R. B., Ferrigno, B. W., Morales, E. M., Castro, C. M., Goyes, D., Trivedi, H. D., Patwardhan, V. R., & Bonder, A. (2023) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2023.22239 · Cited by 43
Zhang, Y., LaCerte, C., Kansra, S., Jackson, J. P., Brouwer, K. R., & Edwards, J. E. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.368 · Cited by 35
Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis
Li, Y., Li, B., You, Z., Zhang, J., Wei, Y., Li, Y., Chen, Y., Huang, B., Wang, Q., Miao, Q., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.06.004 · Cited by 35
Antihepatic Fibrosis Drugs in Clinical Trials
Guo, Y., & Lu, L. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00023 · Cited by 44
“OCA has also been widely used in clinical trials for PBC. Nevens et al.20 conducted a phase III clinical trial in PBC patients with inadequate response to conventional drugs.”
BackgroundBile acids regulate lipid metabolism through selective actions on fatty acid absorption
Chan, A. P., Jarrett, K. E., Lai, R. W., Brearley-Sholto, M. C., Cheng, A., Taveras, M. O., Iwata, A. M., Steel, M. E., Lau, A., Whang, E. C., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.010 · Cited by 42
Primary biliary cholangitis: Personalizing second-line therapies
Levy, C., & Bowlus, C. L. (2024) · Hepatology · doi:10.1097/hep.0000000000001166 · Cited by 44
Self-citationSmets, L., Verbeek, J., Korf, H., van der Merwe, S., Nevens, F., et al. (2021) · Hepatology · doi:10.1002/hep.31613 · Cited by 34
“(1) Obeticholic acid (OCA) is the approved second-line therapy if ursodeoxycholic acid (UDCA) fails, but its use may worsen pruritus.(2) Adding bezafibrate to UDCA improved biochemical markers of cholestatic liver injury and decreased pruritus severity.”
BackgroundMethodSelf-citationLee, Y., Kim, B.-R., Kang, G.-H., Lee, G. J., Park, Y. J., Kim, H., Jang, H. C., & Choi, S. H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1100 · Cited by 35
“A clinical trial of obeticholic acid in NAFLD showed more episodes of pruritis, reversible heart failure, osteopenia, lower HDL-C levels, higher LDL-C levels, and more severe fatigue compared with placebo group despite improvement of liver histology through FXR agonism [36].”
BackgroundGazda, J., Dražilová, S., Gazda, M., Janíčko, M., Koky, T., Macej, M., Carbone, M., & Jarčuška, P. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.12.010 · Cited by 40
Flinders, B., Huizing, L. R. S., van Heerden, M., Cuyckens, F., Neumann, U. P., van der Laan, L. J. W., Damink, S. W. M. O., Heeren, R. M. A., Schaap, F. G., & Vreeken, R. J. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b01378 · Cited by 36
Sorda, J. A., Ballerga, E. G., Barreyro, F. J., Avagnina, A., Carballo, P., de Lima, A. P., & Daruich, J. R. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16618 · Cited by 35
The Human Gut Microbiome in Liver Diseases
Davis, B., & Bajaj, J. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1602763 · Cited by 34
Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
Fiorucci, S., Urbani, G., Distrutti, E., & Biagioli, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091424 · Cited by 47
“…5–10 mg, was granted conditional approval by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as a second-line treatment of patients with primary biliary cholangitis (PBC) [67,68] (Table 2) who had an inadequate response to UDCA or were unable to tolerate it [67,68].”
InfluentialObeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns
Pοlyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154144 · Cited by 35
Chronic Complications of Cholestasis
Assis, D. N. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.014 · Cited by 36
Ng, C. H., Tang, A. S. P., Xiao, J., Wong, Z. Y., Yong, J. N., Fu, C. E., Zeng, R. W., Tan, C., Wong, G. H. Z., Teng, M. L. P., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000005 · Cited by 38
“[17] In PBC and PSC, several trials including a phase 3 study (POISE) have demonstrated significant improvements in biochemical measurements which can be predictive of improved long-term clinical outcomes.[20] However, despite the significant finding impact of the finding, there remains preexisting safety concerns wit…”
BackgroundResultInfluentialZhu, Q., Yuan, C., Dong, X., Wang, Y., Li, B., Tu, B., Chen, W., Xu, X., Gong, W., Xiao, W., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101304 · Cited by 50
“25 Considering the potential for future clinical translation of this drug, we similarly performed in vitro cell experiments with OCA.”
MethodSun, G., Jackson, C. V., Zimmerman, K. M., Zhang, L., Finnearty, C., Sandusky, G. E., Zhang, G., Peterson, R. G., & Wang, Y. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-0958-4 · Cited by 41
“It was originally developed for the treatment of primary biliary cholangitis [48] and is currently in the most advanced stage being tested for NASH”
BackgroundLiver fibrosis: pathological features, clinical treatment and application of therapeutic nanoagents
Chen, L., Guo, W., Mao, C., Shen, J., & Wan, M. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02790b · Cited by 38
The Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer’s Disease
Ehtezazi, T., Rahman, K., Davies, R., & Leach, A. G. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220071 · Cited by 41
“[376, 377] Obeticholic acid 5-10 mg Selective farnesoid X receptor agonist 12 months Significantly reduced plasma bile acid levels including C4 Pruritus [346, 378] Maralixibat 20 mg Apical sodium dependent bile acid competitive inhibitor 13 weeks Reduced serum bile acids from 52 ng/ml to 33 ng/ml Gastrointestinal diso…”
BackgroundCurrent epidemiology and clinical characteristics of autoimmune liver diseases in South Korea
Jeong, S. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2017.0066 · Cited by 35
MicroRNAs in autoimmune liver diseases: from diagnosis to potential therapeutic targets
Huang, C., Xing, X., Xiang, X., Fan, X., Men, R., Ye, T., & Yang, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110558 · Cited by 32
Additional fibrate treatment in UDCA‐refractory PBC patients
Chung, S. W., Lee, J., Kim, M. A., Leem, G., Kim, S. W., Chang, Y. W., Lee, H. Y., Yoon, J. S., Park, J. Y., Lee, Y. B., et al. (2019) · Liver International · doi:10.1111/liv.14165 · Cited by 35
Biagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 37
The Microbiome and Hepatocellular Carcinoma
Rattan, P., Minacapelli, C. D., & Rustgi, V. K. (2020) · Liver Transplantation · doi:10.1002/lt.25828 · Cited by 34
“Alternatively, FXR agonists, including obeticholic acid, have already been approved for use in CLDs, such as primary biliary cholangitis,(84) and have shown promising effects on fibrosis associated with NASH.”
Gerdes, V. E. A., Gueimonde, M., Pajunen, L., Nieuwdorp, M., & Laitinen, K. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.028 · Cited by 39
Zhang, S., Yu, M., Guo, F., Yang, X., Chen, Y., Ma, C., Li, Q., Wei, Z., Li, X., Wang, H., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14886 · Cited by 33
“Hypercholesterolemia is commonly found in cholestatic patients (Dann et al., 2006; Gylling, Farkkila, Vuoristo, & Miettinen, 1995) and treatment with UDCA has little effect on this disorder while obeticholic acid exacerbates hypercholesterolemia (NeuschwanderTetri et al., 2015; Nevens et al., 2016).”
BackgroundApplication of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis
Kowdley, K. V., Bowlus, C. L., Levy, C., Mayo, M. J., Pratt, D. S., Vuppalanchi, R., & Younossi, Z. M. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002070 · Cited by 35
“ULN were associated with adverse liver-related outcomes (32,33).”
BackgroundInfluentialSelf-citationNew Therapies on the Horizon for Primary Biliary Cholangitis
Tanaka, A. (2023) · Drugs · doi:10.1007/s40265-023-01979-1 · Cited by 33
“The endpoints were met in 10, 46, and 47% of the placebo, 5–10 mg OCA-, and 10 mg OCA-treated patients, respectively [10].”
Targeting bile acids and lipotoxicity for NASH treatment
Chiang, J. Y. L. (2017) · Hepatology Communications · doi:10.1002/hep4.1127 · Cited by 32
Animal Models of Autoimmune Liver Diseases: a Comprehensive Review
Liu, S.-P., Bian, Z.-H., Zhao, Z.-B., Wang, J., Zhang, W., Leung, P. S. C., Li, L., & Lian, Z. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08778-6 · Cited by 42
Gupta, V., Sehrawat, T. S., Pinzani, M., & Strazzabosco, M. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.07.044 · Cited by 43
Hirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., et al. (2026) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(25)00192-x · Cited by 34
Self-citationLipidomics analysis in drug discovery and development
Kostidis, S., Sánchez‐López, E., & Giera, M. A. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102256 · Cited by 33
Palmer, M., Regev, A., Lindor, K. D., Avigan, M., Dimick‐Santos, L., Treem, W. R., MARCINAK, J. F., Lewis, J. H., Anania, F. A., Seekins, D. W., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15579 · Cited by 34
Self-citationSasaki, M., Sato, Y., & Nakanuma, Y. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102377 · Cited by 33
Targeting bile acid signaling for the treatment of liver diseases: From bench to bed
Duan, S., Li, X., Fan, G., & Liu, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113154 · Cited by 33
Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions
Zhao, Q., Wu, J., Ding, Y., Pang, Y., & Jiang, C. (2023) · Life Metabolism · doi:10.1093/lifemeta/load032 · Cited by 35
From Liver Fat to Cancer: Perils of the Western Diet
Kim, J. Y., He, F., & Karin, M. (2021) · Cancers · doi:10.3390/cancers13051095 · Cited by 33
Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study
Örnolfsson, K. T., Lund, S. H., Ólafsson, S., Bergmann, O. M., & Bjornsson, E. S. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1606931 · Cited by 32
“The drug was approved in 2016 by the FDA as second-line therapy for patients not responding to UDCA treatment [8].”
BackgroundFiorucci, S., Biagioli, M., Baldoni, M., Ricci, P., Sepe, V., Zampella, A., & Distrutti, E. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1916465 · Cited by 30
Hofer, B., Burghart, L., Halilbasic, E., Simbrunner, B., Petrenko, O., Mandorfer, M., Stättermayer, A. F., Trauner, M., & Reiberger, T. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17908 · Cited by 40
“3 However, 20%–50% 4 of all patients treated with UDCA are identified as non-responders according to Paris II criteria 5 in whom add-on pharmacotherapy with obeticholic acid 1,2,6,7 or bezafibrate 8,9 may be considered.”
BackgroundSelf-citationNew treatments/targets for primary biliary cholangitis
Corpechot, C., Poupon, R. Y., & Chazouillères, O. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.05.005 · Cited by 32
“This goalwas achieved both in patientswith incomplete response or intolerance to UDCA and in UDCA-naive patients.(37,38) OCA is a synthetic bile acid derivativewith a high affinity for FXR, a nuclear receptor that closely regulates bile acid synthesis and secretion, and has been shown to mediate anti-inflammatory and…”
BackgroundMethodSymptoms and health-related quality of life in Japanese patients with primary biliary cholangitis
Yagi, M., Tanaka, A., Abe, M., Namisaki, T., Yoshiji, H., Takahashi, A., Ohira, H., Komori, A., Yamagiwa, S., Kikuchi, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31063-8 · Cited by 35
Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC)
Kaps, L., Grambihler, A., Yemane, B., Nagel, M., Labenz, C., Ploch, P., Michel, M. S., Galle, P. R., Wörns, M., & Schattenberg, J. M. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-06009-3 · Cited by 34
De Vincentis, A., D'Amato, D., Cristoferi, L., Gerussi, A., Malinverno, F., Lleo, A., Colapietro, F., Marra, F., Galli, A., Fiorini, C., et al. (2022) · Liver International · doi:10.1111/liv.15386 · Cited by 30
“Duration of disease before OCA start, years 9 (5, 15) Body Mass Index, Kg/m2 24.”
BackgroundSelf-citationJung, Y., Koo, B. K., Jang, S. Y., Kim, D. R., Lee, H., Lee, D. H., Joo, S. K., Jung, Y. J., Park, J. H., Yoo, T., et al. (2021) · Liver International · doi:10.1111/liv.15030 · Cited by 31
FXR Agonists: From Bench to Bedside, a Guide for Clinicians
Alawad, A. S., & Levy, C. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4334-8 · Cited by 31
“It was reported in 68 % of OCA on 10 mg, 56 % of OCA on 5–10 mg, and 38 % of the placebo group [46].”
BackgroundMethodInfluentialPPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress
Hayes, C. M., Gallucci, G. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000612 · Cited by 35
Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?
Yang, Y., He, X.-S., Rojas, M., Leung, P. S. C., & Gao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1184252 · Cited by 32
“The recommended dose of OCA is 5-10mg, with incidence of pruritus increased with dose (125).”
BackgroundDihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma
Guo, Y., Peng, Q., Hao, L., Ji, J., Zhang, Z., Xue, Y., Liu, Y., Gao, Y., Li, C., & Shi, X. (2022) · The FASEB Journal · doi:10.1096/fj.202200171r · Cited by 30
New Therapeutic Targets in Autoimmune Cholangiopathies
Gerussi, A., Luca, M. D., Cristoferi, L., Ronca, V., Mancuso, C., Milani, C., D’Amato, D., O'Donnell, S. E., Carbone, M., & Invernizzi, P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00117 · Cited by 31
“Baricitinib is already included in the available registered drugs for the treatment of rheumatoid arthritis (59), and was supposed to be evaluated in a randomized double-blind, placebo-controlled, phase 2, study in patients with PBC and partial response to UDCA.”
BackgroundInfluentialSelf-citationLuo, S., Huang, M., Lu, X., Zhang, M., Xiong, H., Tan, X., Deng, X., Zhang, W., Ma, X., Zeng, J., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155573 · Cited by 35
Regulation of autophagy by bile acids and in cholestasis - CholestoPHAGY or CholeSTOPagy
Panzitt, K., Fickert, P., & Wagner, M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166017 · Cited by 33
Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease
van Zutphen, T., Bertolini, A., de Vries, H. D., Bloks, V. W., de Boer, J. F., Jonker, J. W., & Kuipers, F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_233 · Cited by 33
The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
Mazzetti, M., Marconi, G., Mancinelli, M., Benedetti, A., Marzioni, M., & Maroni, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081763 · Cited by 33
“Concerning the lipid profile, a transient increase in LDL and a decrease in HDL, VLDL, total cholesterol, and triglycerides were detected [14,15].”
BackgroundUpdate on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.
Bahar, R., Wong, K. A., Liu, C. H., & Bowlus, C. L. (2018) · Europe PMC (PubMed Central) · Cited by 32
Self-citationTreatment options for nonalcoholic steatohepatitis - a safety evaluation
Issa, D., Wattacheril, J. J., & Sanyal, A. J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1343299 · Cited by 30
“Pruritus is a common and dosedependent AE and may lead to treatment discontinuation in 3–4% of patients [43,86].”
BackgroundOsteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges
Trivedi, H. D., Danford, C. J., Goyes, D., & Bonder, A. (2020) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s204638 · Cited by 33
“Although there was less of a decline in patients on treatment, there was no statistically significant difference.(40) More conclusive evidence of these treatments for the bone-specific complications of PBC is warranted.”
BackgroundCurrent Prevention and Treatment Options for NAFLD
Wong, V. W. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_12 · Cited by 31
Chascsa, D. M. H., & Lindor, K. D. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01664-0 · Cited by 29
Self-citationMechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 36
“Obeticholic acid is a selective FXR agonist was approved for the treatment of PBC due to the positive results from a previous phase 3 study (Nevens et al., 2016).”
Han, S., Wang, K., Shen, J., He, X., Lu, Y., Zhuge, A., Li, S., Qiu, B., Zhang, S., Dong, X., et al. (2023) · Nutrients · doi:10.3390/nu15234864 · Cited by 33
“Obeticholic acid (OCA), an approved clinical agent for PSC, activates the FXR to decrease bile synthesis and increase bile excretion [6].”
BackgroundLiver Biopsy in Primary Biliary Cholangitis
Tan, D., & Goodman, Z. D. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.008 · Cited by 31
Treatment of severe alcoholic hepatitis: past, present and future
Lanthier, N., & Stärkel, P. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12767 · Cited by 29
Carbone, M., Harms, M. H., Lammers, W. J., Marmon, T., Pencek, R., MacConell, L., Shapiro, D., Jones, D. E., Mells, G. F., & Hansen, B. E. (2018) · Hepatology Communications · doi:10.1002/hep4.1180 · Cited by 28
Self-citationHigh-definition PBC: biology, models and therapeutic advances
Webb, G. J., & Hirschfield, G. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.201 · Cited by 31
Self-citationLominchar, P. L., Orue-Echebarria, M. I., Martín, L., Lisbona, C. J., Salcedo, M. M., Olmedilla, L., Sharma, H., Asencio, J. M., & López-Baena, J. Á. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i9.663 · Cited by 37
de Veer, R. C., Harms, M. H., Corpechot, C., Thorburn, D., Invernizzi, P., Janssen, H. L. A., Battezzati, P. M., Nevens, F., Lindor, K. D., Floreani, A., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17226 · Cited by 26
Self-citationPBC-transplantation and disease recurrence
Nevens, F. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.09.001 · Cited by 34
Self-citationGuo, Z., He, K., Pang, K., Yang, D., Lyu, C., Xu, H., & Wu, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084321 · Cited by 31
“Nevertheless, around 30–40% of patients treated with UDCA do not respond adequately, and OCA is reportedly associated with a higher incidence of adverse events [2,5].”
BackgroundChang, J., Go, S., Verhoeven, A. J., Beuers, U. H., & Elferink, R. P. J. O. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.022 · Cited by 32
Self-citationTreatment in primary biliary cholangitis: Beyond ursodeoxycholic acid
van Hooff, M. C., Werner, E., & van der Meer, A. J. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.030 · Cited by 32
Burghart, L., Halilbasic, E., Schwabl, P., Simbrunner, B., Stättermayer, A. F., Petrenko, O., Scheiner, B., Bauer, D. J. M., Pinter, M., Boztuǧ, K., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01839-3 · Cited by 34
“In terms of novel and effective PBC treatments for patients with non-response/intolerance to UDCA or with high-risk of disease progression [12], the reduction of CSPH-associated complications represents a clinically relevant endpoint for future studies [13, 14].”
BackgroundSelf-citationGuidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)
You, H., Duan, W., Li, S., Lv, T., Chen, S., Lu, L., Ma, X., Han, Y., Nan, Y., Xu, X., et al. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00347 · Cited by 45
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape
Bhushan, S. R., Sohal, A., & Kowdley, K. V. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003174 · Cited by 35
Self-citationSchönau, J., Wester, A., Schattenberg, J. M., & Hagström, H. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13624 · Cited by 37
Current Status of Liver Transplantation for Primary Biliary Cholangitis
Aguilar, M. T., & Carey, E. J. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.011 · Cited by 26
Lin, W., Wang, J.-X., & Liu, Y.-J. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02460-0 · Cited by 28
Kim, D. J., Chung, H., Ji, S. C., Lee, S., Yu, K., Jang, I., & Cho, J. (2019) · Metabolomics · doi:10.1007/s11306-019-1494-5 · Cited by 26
Primary Biliary Cholangitis and Autoimmune Hepatitis
González, R. S., & Washington, K. M. (2018) · Surgical pathology clinics · doi:10.1016/j.path.2018.02.010 · Cited by 42
Primary biliary cholangitis: treatment
Cazzagon, N., & Floreani, A. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000708 · Cited by 27
Self-citationCholestatic Itch: Our Current Understanding of Pathophysiology and Treatments
Does, A. V., Levy, C., & Yosipovitch, G. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00710-2 · Cited by 35
“The most common adverse effect of OCA is pruritus of mild to moderate severity (for the NASH trial: 19%, 28%, and 51% of patients receiving placebo, OCA 10 mg, and OCA 25 mg, respectively; for the PBC trial: 38%, 56%, and 68% of patients receiving placebo, OCA 5–10 mg, and OCA 10 mg, respectively) [67, 68].”
BackgroundTrauner, M., Karpen, S. J., & Dawson, P. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001438 · Cited by 32
“…cholestasis and therefore may no longer be amenable to further pharmacological suppression via FXR. [91] In 2016, the FXR agonist obeticholic acid (OCA; 6-ethyl-chenodeoxycholic acid) was conditionally approved as a second-line agent for primary biliary cholangitis (based on NCT01473524 [211] ).”
Self-citationPate, J., Gutierrez, J. A., Frenette, C. T., Goel, A., Kumar, S. R., Manch, R. A., Mena, E., Pockros, P. J., Satapathy, S. K., Yimam, K. K., et al. (2019) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2018-000256 · Cited by 27
“22 While the exact pathophysiology of pruritus in PBC is currently unknown, there are several suggested mechanisms that may work independently or in combination.”
InfluentialSelf-citationAdvances in the diagnosis and treatment of liver fibrosis
Cheng, J. Y., & Wong, G. L. (2017) · Hepatoma Research · doi:10.20517/2394-5079.2017.27 · Cited by 31
“[137] OCA is found to be effective to improve liver biochemistries in a Phase 3 trial.[138]”
BackgroundAccess to care in rare liver diseases: New challenges and new opportunities
Jones, D. E. J., Sturm, E., & Lohse, A. W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.004 · Cited by 30
“• supported trial development and delivery leading to the first new licensed therapy in PBC in 20 years (Obeticholic Acid) and important new options in symptom control [62, 63]”
BackgroundSelf-citationParés, A. R. (2018) · Medicina Clínica · doi:10.1016/j.medcli.2017.12.021 · Cited by 29
Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets
Sato, K., Glaser, S. S., Kennedy, L. L., Liangpunsakul, S., Meng, F., Francis, H., & Alpini, G. D. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1608950 · Cited by 27
Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
Abenavoli, L., Procopio, A. C., Fagoonee, S., Pellicano, R., Carbone, M., Luzza, F., & Invernizzi, P. (2020) · Diseases · doi:10.3390/diseases8020020 · Cited by 26
“The efficacy of OCA was assessed in the POISE study, a double‐blind phase 3 study of 12‐month duration [25].”
MethodSelf-citationWei, X., Ma, Y., Dong, Z., Wang, G., Lan, X., Liao, Z., & Chen, M. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153378 · Cited by 26
Bile acids and their receptors in hepatic immunity
Fiorucci, S., Marchianò, S., Distrutti, E., & Biagioli, M. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.005 · Cited by 31
Current Landscape and Evolving Therapies for Primary Biliary Cholangitis
Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13181580 · Cited by 31
“Therefore, a decrease in butyrate-producing bacteria could result in impaired MDSC function and a suboptimal response to UDCA treatment, suggesting that microbiota-targeted therapies could have therapeutic potential in PBC patients.”
BackgroundUnderstanding and Treating Pruritus in Primary Biliary Cholangitis
Carrion, A. F., Rosen, J. D., & Levy, C. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.005 · Cited by 24
Epidemiological and economical burden of cholestatic liver disease
Mol, B., Werner, E., Culver, E. L., van der Meer, A. J., Bogaards, J. A., & Ponsioen, C. Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001341 · Cited by 31
Metadata
- Authors
- Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., Trauner, M., Jones, D. E., Floreani, A., Hohenester, S., Luketic, V., Shiffman, M., van Erpecum, K. J., Vargas, V., Vincent, C., Hirschfield, G. M., Shah, H., Hansen, B., Lindor, K. D., Marschall, H.-U., Kowdley, K. V., Hooshmand-Rad, R., Marmon, T., Sheeron, S., Pencek, R., MacConell, L., Pruzanski, M., & Shapiro, D.
- Affiliations
- University of Padua (IT)
- Humanitas University (IT)
- University Health Network (CA)
- ORCID
- Nevens, Frederik
- Mazzella, Giuseppe
- Strasser, Simone I.
- Bowlus, Christopher
- Invernizzi, Pietro
- Drenth, Joost P.H.
- Pockros, Paul J.
- Beuers, Ulrich
- Trauner, Michael
- Jones, David E.
- Floreani, Annarosa
- Hohenester, Simon
- Luketic, Velimir
- Shiffman, Mitchell
- Vincent, Catherine
- Hirschfield, Gideon M.
- Shah, Hemant
- Hansen, Bettina
- Lindor, Keith D.
- Marschall, Hanns-Ulrich
- Kowdley, Kris V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-18
- Volume
- 375
- Issue
- 7
- Pages
- 631-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2518389324
- Cited by
- 1,131
- References
- 33
- Citations by year
- 2026: 91 · 2025: 118 · 2024: 108 · 2023: 100 · 2022: 123 · 2021: 115 · 2020: 123 · 2019: 111 · 2018: 129 · 2017: 97 · 2016: 14
- FWCI
- 84.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Intercept Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, ursodeoxycholic acid, alkaline phosphatase, total bilirubin, liver fibrosis, pruritus, liver transplantation, liver cirrhosis, drug safety, dose comparison, noninvasive fibrosis assessment
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bile Acids and Salts, Chenodeoxycholic Acid, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.